New EU approval for Jardiance

The SGLT2 inhibitor drug Jardiance (empagliflozin), developed and marketed by family-owned German pharma major Boehringer Ingelheim and the USA’s Eli Lilly (NYSE: LLY), has won approval from the European Commission for the new indication of chronic kidney disease (CKD).

Boehringer noted that the approval has the potential to advance the standard of care for more than 47 million people in the European Union living with CKD, and help relieve burden on healthcare systems by reducing the risk of all-cause hospitalization for people with CKD.

Jardiance is already Boehringer’s top-selling drug, generating revenues of 5.83 billion euros ($6.45 billion) in 2022, a rise of 48% compared with the year earlier.